, Volume 21, Issue 6, pp 405-407
Date: 10 Nov 2007

Secondary Prevention of Coronary Artery Disease and the Choice of the ACE Inhibitor Why EUROPA and not PEACE

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access
This is an excerpt from the content

ACE inhibitors are widely accepted as anti-hypertensive therapy and considered the cornerstone of heart failure treatment. In addition, in patients at high cardiovascular risk ACE inhibition with ramipril has been shown to reduce cardiovascular events, including myocardial infarction, and death [1]. The EUROPA study was designed to demonstrate that ACE inhibition could also result in secondary prevention of coronary events in a much broader population, patients with stable coronary disease irrespective of risk profile [2]. In that study, the ACE inhibitor perindopril significantly reduced the combined endpoint of cardiovascular death, non-fatal myocardial infarction, and resuscitated sudden cardiac death by 20%, despite the presence of platelet antagonists, beta-blockade and statins in the majority of patients [3]. The efficacy of the ACE inhibitor was comparable in patients with a low, medium or high cardiovascular risk profile [4]. Moreover, the event reduction occurred irrespective ...